-
公开(公告)号：US20230088509A1
公开(公告)日：2023-03-23
申请号：US17999165
申请日：2021-05-19
Applicant: St. Jude Children's Research Hospital
Inventor： Junmin Peng , Hong Wang , Kaushik Kumar Dey
IPC: G01N33/68
Abstract: This disclosure relates to compositions and methods of diagnosing neurodegenerative disease by analyzing protein expression profiles in a subject.
-
公开(公告)号：US20230030680A1
公开(公告)日：2023-02-02
申请号：US17791181
申请日：2021-01-06
Applicant: St. Jude Children's Research Hospital, Inc.
Inventor： Stephen GOTTSCHALK , Laurens SAND , Shannon LANGE
IPC: C07K14/715 , A61K35/17
Abstract: The present invention provides chimeric cytokine receptors, particularly chimeric cytokine receptors that canbe activated in tumor microenvironment, and their uses in tumor immunotherapy (e.g., adoptive cell therapy). The present invention further provides methods of genetically modifying therapeutic cells resulting in an enhanced immune response against a target antigen. The application further provides therapeutic cells that express said chimeric cytokine receptors and methods for treating patients using the modified therapeutic cells.
-
公开(公告)号：US20230021224A1
公开(公告)日：2023-01-19
申请号：US17470678
申请日：2021-09-09
Inventor： Jaeki MIN , Daniel C. SCOTT , Deepak BHASIN , Brenda A. SCHULMAN , Bhuvanesh SINGH , Jared T. HAMMILL , R. Kiplin GUY
IPC: A61K31/4545 , C07D401/12 , C07D211/58 , C07D401/06 , C07D409/14 , C07D405/12 , C07D417/06 , C07D471/04 , C07D405/06 , C07D401/04 , C07D417/04 , A61P31/12 , A61P15/16 , A61P31/04 , A61K31/17 , A61K31/437 , A61K31/451 , A61K31/4525 , A61K31/454 , A61K31/506
Abstract: In one aspect, the invention relates to substituted 1-phenyl-3-(piperidin-4-yl)urea analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the DCN1-UBC12 interaction inhibitors of DCN1-mediated cullin-RING ligase activity, methods of making same, pharmaceutical compositions comprising same, methods of treating disorders using the disclosed compounds and compositions, methods of treating disorders associated with a DCN1-UBC12 interaction dysfunction, methods of treating disorders associated with a DCN1-mediated cullin-RING ligase activity dysfunction, methods of male contraception comprising the disclosed compounds and compositions, and kits comprising the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
-
公开(公告)号：US11547709B2
公开(公告)日：2023-01-10
申请号：US16957996
申请日：2018-12-26
Inventor： Suzanne Jackowski , Charles O. Rock , Richard E. Lee , Lalit Kumar Sharma , Mi Kyung Yun , Chitra Subramanian , Rajendra P. Tangallapally , Anne V. Edwards , Robert Zamboni , T. Jagadeeswar Reddy , Jiuyu Liu
IPC: A61K31/501 , A61P3/00 , A61K31/197 , A61K31/205
Abstract: The present disclosure relates to methods of treating a coenzyme A reduction, elevation, sequestration, toxicity, or redistribution (CASTOR) disease such as, for example, defects in fatty acid oxidation enzymes, methylmalonic acidemia, glutaric acidemia, propionic academia, and HMG-CoA lyase, via small molecule modulators of CoA levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
-
公开(公告)号：US11446308B2
公开(公告)日：2022-09-20
申请号：US16707991
申请日：2019-12-09
Applicant: St. Jude Children's Research Hospital
Inventor： Jian Zuo , Tai Teitz , Jie Fang , Asli Goktug , Taosheng Chen , Jaeki Min , R. Kiplin Guy
IPC: A61K31/55 , A61K31/4015 , A61K31/454 , A61K31/404 , A61K31/506 , A61K31/52 , A61K31/519 , A61K31/4155 , A61P27/16
Abstract: In one aspect, pharmaceutical compositions comprising a CDK2 inhibitor and one or more of at least one agent known to treat a hearing impairment and at least one agent known to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
-
Patent Agency Ranking
公开(公告)号：US20220226380A1
公开(公告)日：2022-07-21
申请号：US17605639
申请日：2020-04-23
Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
Inventor： Hongbo CHI , Jun WEI , Terrence GEIGER , Wenting ZHENG
IPC: A61K35/17 , C12N15/90 , C12N15/11 , C12N9/22 , C12N9/10 , C12N9/16 , A61P35/00 , C07K14/47 , A61K38/46 , A61K31/7088 , C12N15/86 , C07K16/28 , C07K14/705 , C07K14/725
Abstract: The present application provides methods of enhancing T cell function (e.g., expansion, persistence and/or effector functions), particularly by genetic modification of the Regnase-1, Batf, and additional genes (alone or in combination). The application also provides modified T cells manufactured using the methods provided by this invention and related pharmaceutical compositions. The application further provides methods of using the modified T cells for treating a disease (e.g., a cancer or an infectious disease).
-
公开(公告)号：US20220226379A1
公开(公告)日：2022-07-21
申请号：US17602524
申请日：2020-04-08
Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
Inventor： Stephen GOTTSCHALK , Giedre KRENCIUTE , Christopher PETERSEN , Benjamin YOUNGBLOOD
IPC: A61K35/17 , A61P35/02 , A61K35/545 , C12N9/10
Abstract: The application provides modified immune effector cells wherein the DNA (cytosine-5)-methyltransferase 3A (DNMT3A)-mediated de novo DNA methylation of the cell genome is inhibited, and STAT5 signaling pathway is activated. The application also provides related pharmaceutical compositions and the methods for generating such modified immune effector cells. The application further provides uses of such modified immune effector cells for treating diseases such as cancers, infectious diseases and autoimmune diseases.
-
公开(公告)号：US11371095B2
公开(公告)日：2022-06-28
申请号：US17166549
申请日：2021-02-03
Applicant: St. Jude Children's Research Hospital, Inc.
Inventor： Shengdar Q. Tsai , Cicera R. Lazzarotto
IPC: C12Q1/6874 , C12N15/10 , C40B40/06 , C40B50/06
Abstract: The invention relates to a high-throughput method for characterizing the genome-wide activity of editing nucleases in vitro.
-
公开(公告)号：US20220185796A1
公开(公告)日：2022-06-16
申请号：US17598163
申请日：2020-03-26
Applicant: St. Jude Children's Research Hospital
Inventor： Ragendra P. Tangallapally , Richard E. Lee , Anne V. Edwards , Charles O. Rock , Suzanne Jackowski , Mi Kyung Yun , Chitra Subramanian
IPC: C07D403/04 , C07D513/04 , C07D498/04 , C07D403/08 , C07D495/04 , C07D413/04 , C07D417/04
Abstract: The present disclosure relates to chemical compounds that modulate pantothenate kinase (PanK) activity for the treatment of metabolic disorders (such as diabetes mellitus type II), neurologic disorders (such as pantothenate kinase-associated neurodegeneration), pharmaceutical compositions containing such compounds, and their use in treatment. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
-
公开(公告)号：US20220125805A1
公开(公告)日：2022-04-28
申请号：US17428812
申请日：2020-02-06
Inventor： Michelle M. MARTINEZ-MONTEMAYOR , Fatima RIVAS
IPC: A61K31/575 , A61K36/074 , A61K47/20 , A61P35/00 , G01N33/58
Abstract: The bioactive compounds of Ganoderma lucidum extract (GLE) responsible for anticancer activity were elucidated using NMR, X-ray crystallography and analogue derivatization, as well as anti-cancer activity studies. Structures of the seven most abundant GLE compounds are disclosed. Their selective efficacy against triple negative (TNBC) and inflammatory breast cancers (IBC) and other human cancer cell types (solid and blood malignancies) was shown, confirming potential their as anticancer agents.
-
-
-
-
-
-
-
-
-
Search Results
329
records
(took 0.026 seconds)
